GPBAR1 and liver disorder: Previous studies have shown that in the liver CSE expression/activity is increased by Farnesoid-x-receptor (FXR) ligands [18] but, whether GPBAR1 protects against development of endothelial dysfunction in rodent models of portal hypertension is unknown.